ERBE-ELEKTROMEDIZIN
6.6.2024 08:12:27 CEST | Business Wire | Press release
Erbe Elektromedizin has inaugurated a new production and development building in Rangendingen, Germany, after three years of construction. At 90 million euros, the new 25,000 m² building is the largest single investment in the company's history and represents another important part in the global network. The building combines production, product development, logistics and administration. Erbe will now develop and produce medical technology instruments for customers all over the world at its Rangendingen site near Tübingen. With the new building, the company is expanding its capacities and is even better equipped to deal with the consequences of global crises. The building is a pioneering achievement in terms of ecological, social and economic sustainability. Among the guests on May 3 were the Chairman of the Free Democratic Party, Christian Lindner, and the Minister of Economic Affairs of Baden-Württemberg, Dr. Nicole Hoffmeister-Kraut.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240603323747/en/
New Erbe production and development building in Rangendingen, Germany (Photo: Business Wire)
On May 3rd, Erbe opened its newest plant in Rangendingen near Tübingen. The new competence center is dedicated to the development and production of medical instruments for our customers around the world. Erbe is expanding its capacities in order to be even more robust in case of supply bottlenecks resulting from international crisis. In this manner, Erbe ensures uninterrupted business operations. This enables us to consistently deliver the highest quality to our customers worldwide.
An important aspect for ensuring continuous economic success is the concept of sustainability. For Erbe, “Made in Germany” means the future of Germany as a business location in harmony with innovative medical technology and a pioneering role for sustainable, responsible entrepreneurship.
“Erbe is a symbol of what makes our country strong,” explained Christian Lindner, Chairman of the Free Democratic Party (FDP) in his speech. He commended the location decision and emphasized the importance of supporting family businesses, stating, “They are the ones who create prosperity.”
“We have set the course for a new standard with our construction project in Rangendingen,” explains Marcus Felstead, Chief Commercial Officer.
“Because tomorrow's customers will place even more value on sustainability than we already do today. We want to meet these demands.”
Both planning and construction of the building had this as a goal. In order to realize ecological, social and economic aspects of the corporate strategy and combine them in an industrial building, Erbe relied on the use of high-quality ecological building materials for the supporting structure and the façade, the use of renewable energy technology and the implementation of numerous measures for an optimal working environment for employees.
A highlight of the building is one of the largest photovoltaic systems in the region. The 2,800 solar panels on the roof with an output of 1 MW produce 610,000 kWh of electricity per year and cover a third of the energy required for operations. This is supplemented by a combined heat and power plant powered by CO2-neutral biogas.
“We implemented the most demanding standards for energy efficiency and achieved KfW Efficiency Level 40 Plus,” explains Christian O. Erbe. “This means, that our building is more than twice as energy efficient compared to conventional structures, making it a leader in the field of sustainable industrial building.”
Up to 500 employees will be working on site. They benefit from a modern, employee-centered working environment. The company's social responsibility also includes a distinctive health concept for employees, including company medical care, health weeks and financial support for sporting activities. There are exercise islands in the building for fitness, a room for yoga, leisure activities and relaxation rooms.
About Erbe Elektromedizin
Erbe Elektromedizin develops, manufactures, and distributes surgical instruments and devices worldwide, while providing services for professional use of these products in a diverse range of medical disciplines. Surgeons, OP teams and patients around the world rely on Erbe medical technology. The surgical instruments and devices find use in almost all specialist areas. They are based on electrosurgery combined with other Erbe technologies. Hybrid solutions enable us to provide new, innovative applications in medicine.
Fields of activity
- Imaging
- Endoscopy
- Electrosurgery
- Plasma surgery
- Thermofusion
- Hydrosurgery
- Cryosurgery
An international network
- 18 international sales and service units
- 4 production sites
- Erbe is active in 110 international markets.
The Erbe workforce
- Over 1,900 employees worldwide
- Some 1,000 of them in Germany
Erbe Elektromedizin GmbH
Waldhoernlestr. 17,
72072 Tübingen
www.erbe-med.com
info@erbe-med.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240603323747/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press release
- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of <30 mmol/L; Vertex on track to initiate global regulatory submissions in first half of 2026 - - Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 12:41:00 CEST | Press release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict
Renewable Electricity, Soft Wheat Flour From Regenerative Agriculture, Initiatives to Support Local Communities: Barilla Shares These and Other Projects in “Stories of Sustainability.”5.6.2026 10:00:00 CEST | Press release
Barilla continues to advance its commitment to tastier products with less sugar and salt;An investment of 30 million euros in 2025 to quadruple photovoltaic capacity across plants, as part of a €168 million five-year plan focused on energy efficiency, renewable energy and sustainable water management.Barilla continues to expand regenerative agriculture practices across its global value chain, with over 816,000 tons of raw materials sourced through the Barilla Sustainable Farming program.4,000 tons of products donated worldwide and €2 million allocated to social causes in 2025, supporting communities across Barilla’s global footprint through food donations and social initiatives. A slimmer Tagliatelle pack that saves 150 tons of cardboard and cuts transport-related CO₂ emissions by 20%1; ready-made sauce jars made with around 65% recycled glass; the progressive scaling of regenerative agriculture practices across Barilla’s value chain and initiatives supporting inclusion and equal oppor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom